Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | CTSG | P08311 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22117681 | 0.86 | SMN1; SMN2 (0.42) | MAPTALDH1A1LMNANFKB1NFKB2 | |
| SCHEMBL31612903 | 0.86 | SMN1; SMN2 (0.42) | MAPTALDH1A1LMNANFKB1NFKB2 | |
| SCHEMBL1835614 | 0.86 | SMN1; SMN2 (0.42) | MAPTALDH1A1LMNANFKB1NFKB2 | |
| SCHEMBL8659028 | 0.84 | RAB9A (0.47) | MAPTALDH1A1LMNAGAANFKB1 | |
| SCHEMBL5467460 | 0.83 | TSHR (0.50) | ALDH1A1MEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL1335543 | 0.82 | ELANE (0.36) | ALDH1A1ELANECTSGGAANFKB1 | |
| SCHEMBL8246260 | 0.81 | TSHR (0.32) | TSHR | |
| SCHEMBL8253083 | 0.81 | TSHR (0.32) | TSHR | |
| SCHEMBL754805 | 0.81 | HTR2C (0.54) | SMN1; SMN2 | |
| SCHEMBL1170552 | 0.81 | HTR2C (0.54) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1853586-B1 | ANTIBACTERIAL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2013-07-24 | — | — | EP | disclosed |
| CN-101243068-B | Compounds for the treatment of multi-drug resistant bacterial infections | ASTRAZENECA AB | 2012-08-08 | — | — | CN | disclosed |
| US-20120108577-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| US-8124602-B2 | Compounds for the treatment of multi-drug resistant bacterial infections | ASTRAZENECA AB (SE) | 2012-02-28 | — | — | US | disclosed |
| US-20110092495-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | disclosed |
| EP-2289890-A1 | Compounds for the treatment of multi-drug resistant bacterial infections | AstraZeneca AB (SE) | 2011-03-02 | — | — | EP | disclosed |
| US-7875715-B2 | 6-[({1-[2-(7-methoxy-2-oxoquinoxalin-1(2H)-yl)ethyl]piperidin-4-yl}amino)methyl]-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one; antibacteria; methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant coagulase-negative staphylococci (MRCNS), penicillin-resistant Streptococcus pneumoniae | ASTRAZENECA AB (SE) | 2011-01-25 | — | — | US | disclosed |
| US-20100152441-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | US | disclosed |
| CN-101243068-A | Compounds for the treatment of multi-drug resistant bacterial infections | ASTRAZENECA AB (SE) | 2008-08-13 | — | — | CN | disclosed |
| EP-0154142-B1 | SUBSTITUTED HEXAHYDRO ARYLQUINOLIZINES | MERCK & CO. INC. (US) | 1989-07-12 | — | — | EP | disclosed |
| EP-0121972-B1 | N-ARYL-ALPHA-AMINO-CARBOXAMIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-05-24 | — | — | EP | disclosed |
| US-4690928-A | ANTIDEPRESSANTS, HYPOTENSIVE AGENTS, ANTIDIABETIC, ANTIOBESITY AND ANTICOAGULANT | MERCK & CO., INC. (US) | 1987-09-01 | — | — | US | disclosed |
| US-4673680-A | 1,3,4,6,7,12B-HEXAHYDRO-2H-BENZO(B)(FURO OR THIENO)(2,3-A) QUINOLIZIN-2-YL-AMINE DERIVATIVES | MERCK & CO., INC., A CORP. OF NJ | 1987-06-16 | — | — | US | disclosed |
| EP-0216247-A2 | Use of alpha 2 adrenergic receptor antagonists for the production of pharmaceutical compositions for treating colonic spasm, irritable bowel syndrome and constipation and process for preparing such pharmaceutical compositions | MERCK & CO. INC. (US) | 1987-04-01 | — | — | EP | disclosed |
| EP-0154142-A1 | Substituted hexahydro arylquinolizines | MERCK & CO. INC. (US) | 1985-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092495-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | MAPT 2405/4885ALDH1A1 2130/4885LMNA 2738/4885 |
| US-20120108577-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | MAPT 2405/4885ALDH1A1 2130/4885LMNA 2738/4885 |
| US-20100152441-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | MAPT 2405/4885ALDH1A1 2130/4885LMNA 2738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.